Clinical Trial

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-28; most recent amendment 2026-02-04.
Trial Details
NCT Number NCT06580301
Lead Sponsor Excyte Biopharma Ltd
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 46 participants
Start Date 2024-09-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06